Brought to you by 
Ikaria takes North American rights to Orphan's Lucassin
28 Oct 2008
Executive Summary
Critical care therapeutics developer Ikaria Holdings has licensed North American rights to Orphan Therapeutics' (treatments for serious unmet diseases) Lucassin (terlipressin) for hepatorenal syndrome (HRS).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ikaria takes North American rights to Orphan's Lucassin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice